and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model" to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: http://www.daiichisankyo.com.
About Daiichi Sankyo Europe Daiichi Sankyo's European base is located in Munich and has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: http://www.daiichi-sankyo.eu.
Forward-looking statements This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements.
Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
References:
1) De Caterina, R. et al. Quality of Life and patient satisfaction data in
atrial fibrillation patients stably treated with a VKA vs patients switched from a VKA
to NOAC. [PREFER in AF abstract P6250 for ESC Congress 2014]. 2014.
2) Zamorano, J.L. et al. Trends in antithrombotic management of atrial
fibrillation after the last update of ESC guidelines: follow-up data from the PREFER
in AF registry. [PREFER in AF abstract P6266 for ESC Congress 2014]. 2014.
3) Camm, A. et al. 2012 focused update of the ESC Guidelines for the management
of atrial fibrillation. European Heart Journal. 2012;33:2719-2747.
4) Kirchhof P, et al. Management of atrial fibrillation in seven European
countries after the publication of the 2010 ESC Guidelines on atrial fibrillation:
primary results of the PREvention oF thromboembolic events - European Registry in
Atrial Fibrillation (PREFER in AF). Europace 2013. doi: 10.1093/europace/eut263.
5) Mavrakanas, T., Bounameaux, H. The potential role of new oral anticoagulants
in the prevention and treatment of thromboembolism. Pharmacology & Therapeutics.
2011;130:46-58.
6) Furugohri, T. et al. DU-176b, a potent and orally active factor Xa inhibitor:
in vitro and in vivo pharmacological profiles. Journal of Thrombosis and Haemostasis.
2008;6:1542-9.
7) Camm, A. et al. Guidelines for the management of atrial fibrillation: the
Task Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC). European Heart Journal. 2010;31:2369-429.
8) Le Heuzey et al. Differences among western European countries in
anticoagulation management of atrial fibrillation. Thromb Haemost. 2014;111(5):833-41.
9) Prolongation PREFER in AF. European Multinational Prolongation Registry on
Prevention of Thromboembolic Events in Atrial Fibrillation. DSE-EAF-01-13. Data on
file.
10) PREFER in AF. European Multinational Registry on Prevention of
Thromboembolic Events in Atrial Fibrillation. DSE-EAF-01-11. Data on file.
11) Patient.co.uk. Atrial Fibrillation. http://www.patient.co.uk/pdf/4198.pdf
(2012). Last accessed July 2014.
12) Patient.co.uk. Professional reference. Atrial Fibrillation.
http://www.patient.co.uk/doctor/atrial-fibrillation (2012). Last accessed July 2014.
13) Fuster, V. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients
With Atrial Fibrillation-Executive Summary. Circulation. 2006; 114:700-752.
Date of preparation: August 2014 Job bag: EDX/14/0052
Photo:
http://photos.prnewswire.com/prnh/201409...
